Eddingpharm Licenses Ablynx Nanobody Drug For Greater China Area
This article was originally published in PharmAsia News
Executive Summary
Eddingpharm has licensed a nanobody drug for treating bone-related disorders from Belgian drug maker Ablynx in a deal that begins with a $2.7 million upfront payment, plus the usual milestone payments and royalties of as much as 20%.